Skip to main content

Table 1 Hydroxyproline:proline ratio by treatment group and organ in the TGF-β/CTGF synergy model

From: Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease

Organ Control Treatments
  - TGF-β2 - TGF-β2 TGF-β2
  - - CTGF CTGF CTGF
  - - - - FG-3019
Kidney 0.057 ± 0.001 0.061 ± 0.002 0.059 ± 0.001 0.094 ± 0.0051 0.085 ± 0.0031,3
Liver 0.015 ± 0.001 0.017 ± 0.001 0.016 ± 0.002 0.039 ± 0.0031 0.032 ± 0.0021,4
Lung 0.079 ± 0.002 0.078 ± 0.002 0.083 ± 0.001 0.088 ± 0.0012 0.083 ± 0.002,3
Heart 0.041 ± 0.001 0.044 ± 0.002 0.046 ± 0.002 0.055 ± 0.0021 0.053 ± 0.0031
  1. Data shown represent mean ± SEM, n = 6 to 10.
  2. 1P < 0.001, 2P < 0.01 compared with healthy control group, one way analysis of variance, Fisher's least significant difference.
  3. 3P < 0.05, 4P < 0.01 compared with transforming growth factor (TGF)-β2 and connective tissue growth factor (CTGF) coadministration group.